Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 22:37:36-37.
doi: 10.1016/j.euros.2021.12.012. eCollection 2022 Mar.

Abandon the Label of Clinically Insignificant Prostate Cancer

Laura S Mertens  1 , Pim J van Leeuwen  1 , Henk G van der Poel  1   2
Affiliations
Editorial

Abandon the Label of Clinically Insignificant Prostate Cancer

Laura S Mertens et al. Eur Urol Open Sci. .
No abstract available

PubMed Disclaimer

References

    1. Osses D.F., Remmers S., Schröder F.H., van der Kwast T., Roobol M.J. Results of prostate cancer screening in a unique cohort at 19 yr of follow-up. Eur Urol. 2019;75:374–377. - PubMed
    1. Mottet N., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–262. - PubMed
    1. Tosoian J.J., Mamawala M., Epstein J.I., et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020;77:675–682. - PubMed
    1. Bryant R.J., Oxley J., Young G.J., et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int. 2020;125:506–514. - PMC - PubMed
    1. Page E.C., Bancroft E.K., Brook M.N., et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831–842. - PMC - PubMed

Publication types

LinkOut - more resources